LabConnect Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members

February 04, 2025 05:02 AM AEDT | By Cision

LabConnect Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members — Image source: Kalkine Media

Recent News

Hawo’s Story: How One Mother Persevered To Feed Her Family

Analysts explain why Hims & Hers stock is crashing today

Coinbase shares rise as SEC set to drop case

Funnelmax: The Innovative, Versatile Tool Revolutionizing Multiple Ind...

JOHNSON CITY, Tenn., Feb. 4, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its inaugural members. This board will further cement LabConnect's position as a global leader in the industry, supporting its ongoing international expansion and significant investments in innovation and technology. The Strategic Advisory Board has been specifically designed to accelerate LabConnect's goal of delivering more efficient, transparent, sustainable, and insightful solutions for its clients and partners.

The distinguished members of the Strategic Advisory Board include:

Scott Evangelista
Mr. Evangelista brings over 30 years of pharmaceutical leadership experience to the board. He is currently the CEO of Cairn Therapeutics, Inc., where he directs the company's strategy, fundraising, and stakeholder management. Previously, Scott served as Executive Chairman at Cairn and has held prominent roles such as President and COO of Ironshore Pharmaceuticals, President of Integrated Health Services at IQVIA (formerly Quintiles), and Principal of the Life Sciences Commercial practice at Deloitte Consulting. Additionally, he sits on the Board of Worldwide Clinical Trials. Scott's extensive background in pharmaceutical leadership and strategic management will be instrumental in driving LabConnect's growth and innovation.

David Johnston, Ph.D.
Dr. Johnston joins the board with a robust background in scientific and operational leadership. As the Senior Vice President and President of Clinical Research at Thermo Fisher, following the acquisition of PPD, David has led global clinical development and laboratory services at PPD and LabCorp, as well as scientific advisory roles at numerous bioscience CROs. His deep knowledge in clinical development operations and patient recruitment will enhance LabConnect's efforts to boost productivity and reduce clinical development costs.

Patrick Hastings
Mr. Hastings is a highly accomplished operations and business development executive with a proven track record in the pharmaceutical and clinical laboratory sectors. Formerly the Global VP at Labcorp, Patrick led the Central Laboratory Services business unit. His leadership experience spans roles at Eli Lilly, Mossberg Labs, Bayer Healthcare, and Merck & Co. Patrick's expertise in lab and pharmaceutical operations, manufacturing, and supply chain will be pivotal in driving LabConnect's operational excellence and business performance.

"We are delighted to welcome Scott, David, and Patrick to our Strategic Advisory Board," said Wes Wheeler, CEO of LabConnect. "Their combined expertise and leadership will be crucial in advising LabConnect as we continue to innovate and expand our global footprint. This board will play a vital role in helping us deliver exceptional value to our clients and partners."

LabConnect remains committed to creating healthier communities by supporting our clients in successfully developing new medicines for patients around the world. The formation of the Strategic Advisory Board marks a significant milestone in LabConnect's ongoing journey to solidify its position as a global leader in the industry.

About LabConnect
LabConnect is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs. Learn more at www.labconnect.com and follow on LinkedIn.

LabConnect US Headquarters

Logo - https://mma.prnasia.com/media2/2611513/LabConnect_Logo.jpg?p=medium600

Photo - https://mma.prnasia.com/media2/2611514/LabConnect_US_Headquarters.jpg?p=medium600

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Full Name

Mobile

By submitting your details above and clicking on the 'Download Report' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.

Markets

Disclaimer

Recent Articles

1

2

3

4

5

Investing Tips

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27